Drug Profile
Research programme: multiple sclerosis therapeutics - CombinatoRx
Alternative Names: CRx-153Latest Information Update: 14 Aug 2009
Price :
$50
*
At a glance
- Originator CombinatoRx
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Multiple sclerosis
Most Recent Events
- 14 Aug 2009 Discontinued - Preclinical for Multiple sclerosis in USA (unspecified route)
- 14 Nov 2007 CRx 153 is available for licensing (http://www.combinatorx.com)